Abstract
An episode of malignant hyperthermia occurring in a two-year-old child undergoing cardiac surgery is re-ported. The coincidental usage of hypothermic cardio-pulmonary bypass obscured the classical presenting signs and symptoms of the syndrome. Once the clinical diagnosis was confirmed, rapid reversal was achieved with the administration ofdantrolene sodium.
Résumé
Un épisode d’hyperthermie maligne ayant survenu chez un enfant de 2 ans subissant une chirurgie cardiaque est rapporté. L’utilisation de l’hypothermie lors de la circu-lation extra-corporelle a obscursi les signes classiques ainsi que les symptômes annonçants ce syndrome. Lorsque le diagnostic clinique a ete confirme, le retablis-sement rapide a été acquis avec l’administration du dantrolène.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Britt, BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970; 17:293–315.
Denborough MA, Forster JFA, Lovell RRH, Mapleston PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth 1962 34:395–6.
Gordon RA, Britt BA, Kalow W (Eds). International symposium on malignant hyperthermia. Springfield, Illinois, Charles C. Thomas, 1973.
Aldrete JA, Britt BA (Eds). Second international symposium on malignant hyperthermia. New York, Grune and Stratton, 1978.
Gronert GA. Malignant hyperthermia. Anesthesiology 1980; 53:395–423.
Britt BA. Malignant hyperthermia. Can. Anaesth Soc J 1985; 32:666–77.
Britt BA. Dantrolene. Can Anaesth Soc J 31:1984;61–75.
Ryan JF, Donlon JV, Malt RA et al. Cardiopulmonary bypass in the treatment of malignant hyperthermia. New Engl J Med 1974; 290:1121–2.
Byrick RJ, Rose DK, Ranganathan N. Management of a malignant hyperthermia patient during cardiopulmonary bypass. Can Anaesth Soc J 1982; 29:50–4.
Nelson TE, Flewellen EH. The malignant hyperthermia syndrome. New Engl J Med 1974; 309:416–8.
Moyes DG. Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 1973; 45:1163–4.
Baudendistel L, Goudsouzian N, Cote C, Strqfford M. End-tidal CO2 monitoring, its use in the diagnosis and management of maligant hyperthermia, Anaesthesia 1984; 39:1000–3.
Sladen RN. Management of the adult cardiac patient in the intensive care unit. In: Acute cardiovascular mangement. Ream AK, Fogdall RP (Eds), Philadelphia. JB Lippincott Company, 1982; 481–548.
Sladen RN. Temperature and ventilation after cardiopulmonary bypass. Anesth Analg 1985; 64:816–20.
Loomis JC. Care of the pediatric patient following cardiovascular surgery.In: Acute cardiovascular management. Ream AK, Fogdall RP (Eds) Philadelphia, JB Lippincott Company 1982, 633–700.
Nevins MA, Savan M, Bright M, Lyon LJ. Pitfalls in interpreting serum creatine phosphokinase activity. JAMA 1973; 224:1382–7.
Kolb ME, Home ML, Marz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982; 56:254–62.
Lieberman P, laina A, David R et al. Nonoliguric acute renal failure following malignant hyperthermia. Second international symposium on malignant hyperthermia. Aldrete JA, Britt BA (Eds) New York, Grune and Stratton, 1978: 541–71.
Gronert GA. Human malignant hyperthermia awake episodes and correction by dantrolene. Anesth Analg 1980; 59:377–8.
Kurlan R, Hamill R, Shoulson J. Neuroleptic malignant syndrome. Clinical Neuropharmacology 1984; 7:109–20.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MacGillivray, R.G., Jann, H., Vanker, E. et al. Development of malignant hyperthermia obscured by cardiopulmonary bypass. Can Anaesth Soc J 33, 509–514 (1986). https://doi.org/10.1007/BF03010981
Issue Date:
DOI: https://doi.org/10.1007/BF03010981